News

Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting.

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products.

A new phaco tip (Fine Ozil Tip, MicroSurgical Technology) for use with a proprietary handpiece (Ozil, Alcon Laboratories) improves the safety and efficiency of phacoemulsification using torsional ultrasound with a biaxial microincisional technique. Modification of the phaco parameters improves chopping and segment removal.

Dr Stephen Lane believes that the large variety of available ophthalmic viscosurgical devices now allows the surgeon to tailor the surgery to meet any specific needs a patient may have.

Anti-VEGF monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement of stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections.

An ophthalmic viscosurgical device is a helpful adjuvant in a multimodal approach for performing cataract surgery in patients with intraoperative floppy iris syndrome, according to three surgeons.

Diagnosing and managing dry eye patients can be challenging. Here Dr Philipp Steven looks at a new way of treating tear film osmolarity, the TearLab Osmolarity System, which he believes could dramatically simplify the process.

A review of more than 20,000 glaucoma patients in Germany has discovered that 52.6% have a concomitant diagnosis of dry eye with women more likely to have both diseases than men.

Dr Randolph Evans argues that endocyclophotocoagulation (ECP) is a simple, safe and effective procedure for achieving IOP lowering in patients with medically controlled glaucoma who also require cataract surgery

My Europia

Myopia is a worldwide public health problem and the underlying mechanisms of its development are still unclear. Currently the key challenge is to attract, train and retain young researchers to the field. The European Research Training Network 'MY EUROPIA' adresses these urgent challenges, by innovative and attractive training and networking possibilities and by the establishment of closer private-public partnership links.

Dr David Tanzer explains that in order to achieve the best possible post-operative results with laser vision correction, thorough pre-operative examinations are a must. Patients should be carefully screened, comprehensive clinical work-ups must be carried out and detailed informed consent given. Then, and only then, will surgeons achieve the best results.

Researchers are looking into corneal biomechanics as a means to screen patients for keratectasia. The authors review signal interpretation from a non-contact applanation tonometer as it relates to corneal biomechanical indices such as corneal hysteresis.

Following intrastromal corneal ring sement implantation five years ago for the management of keratoconus, The Journal of Cataract & Refractive Surgery has published long-term follow up results.

LX214, a topical mixed nanomicellar formulation of voclosporin, has completed its Phase 1 human safety and an open-label pilot efficacy study and is being heralded by its maker Lux Biosciences as a promising treatment for dry eye.

Dr Jorge Alio, a valued member of Ophthalmology Times Europe?s Editorial Advisory Board, has been acknowledged by The Cornea Research Foundation of America (CRFA) for his technique using Yag laser treatments to eliminate epithelial ingrowth after Lasik.

Bromfenac to come to Europe

Bromfenac ophthalmic solution will come to Europe when it comes to market thanks to a co-promotion between Bausch & Lomb and CROMA Pharma.

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.